Newsbenzinga
Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model
· Published
Article summary
As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and specialty grocers win.
An excerpt from the original article.
Comments —
Loading comments…